Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. 600613.SS SHH · Healthcare · China
¥6.23 -6.17% -¥0.41
Summary
36 / 100 · Bulios Score
What speaks for it
- It holds more cash than debt: ¥557.9M against ¥71.1M.
- It has been profitable 5 years in a row.
What to watch
- It pays out more in dividends than it earns: 432% of profit.
- Revenue fell by 6.5% a year over the last 3 years.
- Out of every 100 CNY of revenue, only 0.5 CNY is left as net profit.
- It earns only 1.2 CNY a year on every 100 CNY of invested capital.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Fairly pricedBy our assumptions the price matches the value of the business: the two differ by less than 10 %.
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 407.9 CNY for 1 CNY of yearly profit. Over the last five years it was 69.9 CNY on average.
Valuation in detailIs it growing?
It is shrinkingRevenue (CNY)
Diluted EPS (CNY)
Revenue grew by 1.4% a year over 5 years. Over the last 3 years it fell by 6.5% a year. Earnings per share fell by 8.0% a year over the last 3 years.
Growth in detailDoes it make money?
ReasonablyWhere 100 CNY of revenue goes
- Cost of sales 57 CNY
- Research and development 1.6 CNY
- Sales and administration 37 CNY
- Taxes and other 4.4 CNY
- Net profit 0.5 CNY
Net profit, industry median (Drug Manufacturers - General) 14 CNY
Out of every 100 CNY of revenue, 0.5 CNY is left as net profit.
Profitability in detailIs it financially healthy?
YesIt could repay all its debt from a single year of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
Small, at risk- Yield
- 1.06%
- Paid out of profit
- 432%
You receive ¥0.07 per share a year. The payout is more than the company can comfortably cover.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detail